Company intelligence / Profile preview

Veminsyn

Zhejiang, China

Ownership: Private
Development stage: Other

Overview

The lead program targets tyrosinase for wound and injury care; platform focuses on sustainable, synthetic biotech-derived bioactives. L'Oréal has invested and partnered with Veminsyn to co-develop sustainable bioactive ingredients for cosmetics and personal care. Clinical results are not yet available – current stage is discovery.

Therapeutic areas: Other
Modalities: Recombinant protein
Industry: Biotech

Partnerships

L’Oréal

Beyond the preview

Go deeper on Veminsyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veminsyn.

Explore the full profile